Dr. Steve Worland, Ph.D., Anadys Pharmaceuticals, Inc. President, CEO, & Director, discusses the latest developments at the company:
Can you describe the top priorities or upcoming milestones for your company?
Anadys is focused on the development of ANA598, our non-nucleoside polymerase inhibitor for the treatment of Hepatitis C. ANA598 is in Phase 2 clinical testing in combination with pegylated interferon-alpha and ribavirin, a current standard of care. We expect to receive safety and response data from the first dose level by year-end and additional on-treatment safety and response data from both cohorts in the study during the first two quarters of 2010.
What is one aspect of your company that you feel would be most attractive or exciting to investors?
Investors should look closely at Anadys today because we have a fully-owned HCV asset, ANA598, in Phase 2 clinical testing with the first data read expected by YE 2009. ANA598 was designed to be compatible with future combination treatment regimens and appears to be complementary to most other HCV products on the market or currently in clinical development. The potency and safety profile of ANA598 in Phase 1 was very favorable.
What is the history or story behind your company name?
The name Anadys is a fusion of two Greek words, Anatoli meaning East and Dysi meaning West. The name alludes to the origin of Anadys, when assets from Europe were combined with assets in the U.S. to form the new company.